peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

GLP-1 receptor agonist · 31 amino acids

Liraglutide

/lir-a-GLOO-tide/FDA-approved ingredient
Loading scientific anatomy…
Interactive anatomy · drag to rotate

02 · Consumer names

One ingredient.
Distinct products.

01

Victoza

Daily subcutaneous injection

Type 2 diabetes and specified cardiovascular risk reduction.

Find official label ↗
02

Saxenda

Daily subcutaneous injection

Chronic weight management in specified populations.

Find official label ↗

Product names are not synonyms for one another. Route, strength, indication, and instructions can differ. Compare with primary label

03 · Mechanism + use

What the molecule does,
and where the label stops.

What it does
Activates GLP-1 receptors to increase glucose-dependent insulin secretion, decrease glucagon, reduce appetite, and delay gastric emptying.Mechanism source
Labeled-use boundary
Victoza and Saxenda are separate products with different target doses and indications.Primary label

04 · Labeled safety

Risk belongs
beside benefit.

Boxed warning

Labels warn about thyroid C-cell tumors observed in rodents; human relevance is unknown.Open boxed warning

Who should avoid it

  • Medullary thyroid carcinoma history
  • MEN 2
  • Serious hypersensitivity
Contraindications

More common effects

  • Nausea
  • Diarrhea
  • Vomiting
  • Decreased appetite
  • Dyspepsia
  • Constipation
Adverse reactions

Important serious risks

  • Pancreatitis
  • Gallbladder disease
  • Hypoglycemia with selected therapies
  • Kidney injury from dehydration
  • Heart-rate increase
Warnings

This is a structured label summary, not a complete prescribing-information substitute and not a personalized risk estimate.

05 · Evidence interpretation

Claims with
their edges visible.

01

Diabetes program

The LEAD program established glycemic efficacy across common comparator settings.

Supporting source
Evidence form
Randomized trials
Keep in view
Results are not interchangeable with the higher-dose weight-management product.
02

Cardiovascular outcomes

A dedicated outcomes trial supports a labeled cardiovascular indication for Victoza.

Supporting source
Evidence form
Event-driven randomized trial
Keep in view
Applies to the trial population.
03

Long-standing safety record

Years of label updates integrate clinical and postmarketing experience.

Supporting source
Evidence form
Regulatory synthesis
Keep in view
Postmarketing reports lack denominators.

06 · Research universe

Reviewed anchors.
Live indexes.

The regulatory label anchors approved use and safety. PubMed and ClinicalTrials.gov expose the broader, continuously changing research universe without pretending every result has been reviewed.

  1. 01Regulatory label
    Victoza prescribing information

    DailyMed label for liraglutide marketed as Victoza.

    Open source ↗
  2. 02Literature index
    Every PubMed result for liraglutide

    Live National Library of Medicine literature search; results are not pre-screened or deduplicated.

    Open source ↗
  3. 03Trial registry
    Every registered study for liraglutide

    Live ClinicalTrials.gov search, including completed, active, and historical records.

    Open source ↗
  4. 04Chemical record
    liraglutide chemical record

    PubChem compound search from the National Library of Medicine.

    Open source ↗